Search - Université Clermont Auvergne Access content directly

Filter your results

4 Results
authFullName_s : Hacene Zerazhi

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03441014v1

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial

Anne Bouvier , Jean-Francois Hamel , Jacques Delaunay , Eric Delabesse , Pierre-Yves Dumas et al.
European Journal of Haematology, 2021, 107 (1), pp.111-121. ⟨10.1111/ejh.13626⟩
Journal articles hal-03604930v1
Image document

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03623649v1

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Francois Guilhot , Françoise Rigal-Huguet , Joëlle Guilhot , Agnès-Paule Guerci-Bresler , Frédéric Maloisel et al.
Journal articles hal-03122967v1